🟢 Corcept Therapeutics is trading 4.1% up today as shares rebound on relacorilant NDA resubmission optimism

Corcept Therapeutics is trading at $89.42 (up 4.1%) as shares rebound following yesterday’s profit-taking.

• Investors remain optimistic after the company outlined plans to resubmit its New Drug Application (NDA) for relacorilant in Cushing’s syndrome.
• The planned resubmission serves as a significant catalyst that recently sparked a strong rally, despite broader weakness across the biotech sector.